1. Home
  2. ORBS vs EDIT Comparison

ORBS vs EDIT Comparison

Compare ORBS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eightco Holdings Inc.

ORBS

Eightco Holdings Inc.

HOLD

Current Price

$0.76

Market Cap

447.0M

Sector

N/A

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.39

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORBS
EDIT
Founded
1966
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
447.0M
432.8M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
ORBS
EDIT
Price
$0.76
$2.39
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
★ $6.10
AVG Volume (30 Days)
★ 14.9M
2.1M
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.50
EPS
★ N/A
N/A
Revenue
$31,820,779.00
★ $31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 132.64
52 Week Low
$0.57
$1.66
52 Week High
$7.17
$3.94

Technical Indicators

Market Signals
Indicator
ORBS
EDIT
Relative Strength Index (RSI) 37.63 41.73
Support Level $0.74 $2.31
Resistance Level $0.92 $3.13
Average True Range (ATR) 0.07 0.20
MACD -0.02 -0.01
Stochastic Oscillator 17.09 18.62

Price Performance

Historical Comparison
ORBS
EDIT

About ORBS Eightco Holdings Inc.

Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: